MedPath

Double-blind Trial of Mannitol Cream to Block the Effect of Capsaicin Cream

Not Applicable
Completed
Conditions
Pain
Interventions
Registration Number
NCT01963910
Lead Sponsor
University of British Columbia
Brief Summary

Capsaicin is a TRPV1 (transient receptor potential vanilloid 1) agonist, causing pain upon application. The investigators wish to determine whether mannitol blocks the effect of capsaicin application. As both cream bases are identical and mannitol addition is the only difference between the creams, if the mannitol cream is more effective in blocking the effect of capsaicin on the TRPV1 (transient receptor potential vanilloid 1) receptor, the investigators will have established that mannitol down-regulates or blocks the TRPV1 (transient receptor potential vanilloid 1) receptor.

Detailed Description

Capsaicin cream, which stimulates the TRPV1 (transient receptor potential vanilloid 1) receptor, causing a burning sensation, will be applied to both halves of the upper lip until a burning sensation with 8/10 intensity on an NRS (Visual Analog Scale) scale is experienced or five minutes have elapsed. Following this, the capsaicin cream will be wiped off and 30% mannitol in vehicle cream ( isopropyl palmitate, caprylic capric triglyceride, propylene glycol, ceteareth 20, cetearyl alcohol, glyceryl stearate, polyethylene glycol 100 stearate, dimethicone, octyldodecanol, lecithin, ethylhexyl glycerin and phenoxy ethanol) will be applied to one half of the upper lip, and vehicle cream alone will be applied to the other half. Cream assignment will be randomized and neither the subject nor the person applying the cream will know which half upper lip has which cream. Every minute for 10 minutes, the heat sensation felt in each half upper lip will be measured, using a visual scale from 0 to 10. A repeated measures analysis of variance will compare the NRS (Visual Analog Scale) scores from the 30% mannitol cream, to the NRS (Visual Analog Scale)scores from the vehicle cream. Significance will be accepted if P less than .05.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
25
Inclusion Criteria
  • Age between 19 and 80 years
Read More
Exclusion Criteria
  • Diet containing capsaicin (Cayenne pepper, capsicum) (spicy foods), more than once a week.
  • Meal containing capsaicin (spicy foods) within 5 days prior to the experiment.
  • Any lesion, cracking, cold sore or abrasion on the lips
  • Inability to tolerate capsaicin containing "spicy foods"
  • Wearing lipstick or lip balm on the upper lip
  • Inability to fill out an NRS pain scale
  • Use of painkilling medication, within 24 hours of the study.
  • Allergy to any of the ingredients of the creams, or to mannitol
  • History of contact or allergic dermatitis
  • Pregnant or nursing women
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Vehicle Creamvehicle creamOnce the capsaicin has been removed, .2 mL of vehicle cream will be applied to the other half of the upper lip and kept there for 10 minutes.
Mannitol in vehicle cream30% Mannitol in vehicle creamOnce the capsaicin has been removed, .2 mL of 30% mannitol in vehicle cream will be applied to one half of the upper lip and kept there for 10 minutes.
Primary Outcome Measures
NameTimeMethod
NRS heat score, once per minute15 minutes per subject

Every minute after capsaicin cream application, subject will indicate NRS (numerical rating scale)heat score. When the score has reached 8/10 or after five minutes, the cream will be removed. The time needed to reach 8/10 heat score and the heat score achieved, or the score at five minutes will be recorded. Following application of the test creams, NRS (Visual Analog Scale) heat scores will be recorded once per minute for each side for 10 minutes.

Secondary Outcome Measures
NameTimeMethod
Side effects of capsaicin cream on upper lipOne hour

The subject will be observed for redness, swelling, or other side effects following the capsaicin cream application. These side effects will be recorded

Trial Locations

Locations (1)

Dr. Helene Bertrand Inc., 220-1940 Lonsdale Ave.

🇨🇦

North Vancouver, British Columbia, Canada

© Copyright 2025. All Rights Reserved by MedPath